U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H28N8O4
Molecular Weight 480.5196
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of COPANLISIB

SMILES

COC1=C(OCCCN2CCOCC2)C=CC3=C1N=C(NC(=O)C4=CN=C(N)N=C4)N5CCN=C35

InChI

InChIKey=PZBCKZWLPGJMAO-UHFFFAOYSA-N
InChI=1S/C23H28N8O4/c1-33-19-17(35-10-2-6-30-8-11-34-12-9-30)4-3-16-18(19)28-23(31-7-5-25-20(16)31)29-21(32)15-13-26-22(24)27-14-15/h3-4,13-14H,2,5-12H2,1H3,(H2,24,26,27)(H,28,29,32)

HIDE SMILES / InChI
Molecular Formula C23H28N8O4
Molecular Weight 480.5196
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Approval Year

Unknown
86413
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:26:49 UTC 2023
Edited
by admin
on Fri Dec 15 17:26:49 UTC 2023
Record UNII
WI6V529FZ9
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
COPANLISIB
INN   USAN   WHO-DD  
USAN   INN  
Official Name English
2-AMINO-N-(7-METHOXY-8-(3-(MORPHOLIN-4-YL)PROPOXY)-2,3-DIHYDROIMIDAZO(1,2-C)QUINAZOLIN-5-YL(PYRIMIDINE-5-CARBOXAMIDE
Common Name English
COPANLISIB [MI]
Common Name English
BAY-80-6946
Code English
2-AMINO-N-(7-METHOXY-8-(3-MORPHOLIN-4-YLPROPOXY)-2,3-DIHYDROIMIDAZO(1,2-C)QUINAZOLIN-5-YL)PYRIMIDINE-5-CARBOXAMIDE
Systematic Name English
BAY80-6946
Code English
copanlisib [INN]
Common Name English
5-PYRIMIDINECARBOXAMIDE, 2-AMINO-N-(2,3-DIHYDRO-7-METHOXY-8-(3-(4-MORPHOLINYL)PROPOXY)IMIDAZO(1,2-C)QUINAZOLIN-5-YL)-
Systematic Name English
BAY 80-6946
Code English
COPANLISIB [USAN]
Common Name English
Copanlisib [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C129825
Created by admin on Fri Dec 15 17:26:49 UTC 2023 , Edited by admin on Fri Dec 15 17:26:49 UTC 2023
FDA ORPHAN DRUG 463314
Created by admin on Fri Dec 15 17:26:49 UTC 2023 , Edited by admin on Fri Dec 15 17:26:49 UTC 2023
WHO-ATC L01XX61
Created by admin on Fri Dec 15 17:26:49 UTC 2023 , Edited by admin on Fri Dec 15 17:26:49 UTC 2023
FDA ORPHAN DRUG 811321
Created by admin on Fri Dec 15 17:26:49 UTC 2023 , Edited by admin on Fri Dec 15 17:26:49 UTC 2023
FDA ORPHAN DRUG 552416
Created by admin on Fri Dec 15 17:26:49 UTC 2023 , Edited by admin on Fri Dec 15 17:26:49 UTC 2023
NCI_THESAURUS C2152
Created by admin on Fri Dec 15 17:26:49 UTC 2023 , Edited by admin on Fri Dec 15 17:26:49 UTC 2023
FDA ORPHAN DRUG 811421
Created by admin on Fri Dec 15 17:26:49 UTC 2023 , Edited by admin on Fri Dec 15 17:26:49 UTC 2023
FDA ORPHAN DRUG 552616
Created by admin on Fri Dec 15 17:26:49 UTC 2023 , Edited by admin on Fri Dec 15 17:26:49 UTC 2023
NDF-RT N0000175605
Created by admin on Fri Dec 15 17:26:49 UTC 2023 , Edited by admin on Fri Dec 15 17:26:49 UTC 2023
FDA ORPHAN DRUG 552516
Created by admin on Fri Dec 15 17:26:49 UTC 2023 , Edited by admin on Fri Dec 15 17:26:49 UTC 2023
EU-Orphan Drug EU/3/18/2064
Created by admin on Fri Dec 15 17:26:49 UTC 2023 , Edited by admin on Fri Dec 15 17:26:49 UTC 2023
Code System Code Type Description
SMS_ID
100000170809
Created by admin on Fri Dec 15 17:26:49 UTC 2023 , Edited by admin on Fri Dec 15 17:26:49 UTC 2023
PRIMARY
NCI_THESAURUS
C96796
Created by admin on Fri Dec 15 17:26:49 UTC 2023 , Edited by admin on Fri Dec 15 17:26:49 UTC 2023
PRIMARY
PUBCHEM
24989044
Created by admin on Fri Dec 15 17:26:49 UTC 2023 , Edited by admin on Fri Dec 15 17:26:49 UTC 2023
PRIMARY
MERCK INDEX
m12036
Created by admin on Fri Dec 15 17:26:49 UTC 2023 , Edited by admin on Fri Dec 15 17:26:49 UTC 2023
PRIMARY
WIKIPEDIA
Copanlisib
Created by admin on Fri Dec 15 17:26:49 UTC 2023 , Edited by admin on Fri Dec 15 17:26:49 UTC 2023
PRIMARY
EVMPD
SUB184952
Created by admin on Fri Dec 15 17:26:49 UTC 2023 , Edited by admin on Fri Dec 15 17:26:49 UTC 2023
PRIMARY
RXCUI
1945077
Created by admin on Fri Dec 15 17:26:49 UTC 2023 , Edited by admin on Fri Dec 15 17:26:49 UTC 2023
PRIMARY
DRUG CENTRAL
5256
Created by admin on Fri Dec 15 17:26:49 UTC 2023 , Edited by admin on Fri Dec 15 17:26:49 UTC 2023
PRIMARY
ChEMBL
CHEMBL3218576
Created by admin on Fri Dec 15 17:26:49 UTC 2023 , Edited by admin on Fri Dec 15 17:26:49 UTC 2023
PRIMARY
FDA UNII
WI6V529FZ9
Created by admin on Fri Dec 15 17:26:49 UTC 2023 , Edited by admin on Fri Dec 15 17:26:49 UTC 2023
PRIMARY
CAS
1032568-63-0
Created by admin on Fri Dec 15 17:26:49 UTC 2023 , Edited by admin on Fri Dec 15 17:26:49 UTC 2023
PRIMARY
DAILYMED
WI6V529FZ9
Created by admin on Fri Dec 15 17:26:49 UTC 2023 , Edited by admin on Fri Dec 15 17:26:49 UTC 2023
PRIMARY
LACTMED
Copanlisib
Created by admin on Fri Dec 15 17:26:49 UTC 2023 , Edited by admin on Fri Dec 15 17:26:49 UTC 2023
PRIMARY
USAN
CD-71
Created by admin on Fri Dec 15 17:26:49 UTC 2023 , Edited by admin on Fri Dec 15 17:26:49 UTC 2023
PRIMARY
INN
9726
Created by admin on Fri Dec 15 17:26:49 UTC 2023 , Edited by admin on Fri Dec 15 17:26:49 UTC 2023
PRIMARY
DRUG BANK
DB12483
Created by admin on Fri Dec 15 17:26:49 UTC 2023 , Edited by admin on Fri Dec 15 17:26:49 UTC 2023
PRIMARY
CHEBI
173077
Created by admin on Fri Dec 15 17:26:49 UTC 2023 , Edited by admin on Fri Dec 15 17:26:49 UTC 2023
PRIMARY
EPA CompTox
DTXSID00145728
Created by admin on Fri Dec 15 17:26:49 UTC 2023 , Edited by admin on Fri Dec 15 17:26:49 UTC 2023
PRIMARY
Related Record Type Details
Structure of COPANLISIB HYDROCHLORIDE HYDRATE
SALT/SOLVATE -> PARENT
CYTOCHROME P450 1A1
METABOLIC ENZYME -> SUBSTRATE
MINOR
PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT BETA ISOFORM
TARGET -> INHIBITOR
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
90% OF METABOLISM
MAJOR
Structure of COPANLISIB HYDROCHLORIDE
SALT/SOLVATE -> PARENT
PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT GAMMA ISOFORM
TARGET -> INHIBITOR
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> SUBSTRATE
PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM
TARGET -> INHIBITOR
MATE-2
TRANSPORTER -> INHIBITOR
IC50
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
ATP-BINDING CASSETTE SUB-FAMILY G MEMBER 2
TRANSPORTER -> SUBSTRATE
PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT ALPHA ISOFORM
TARGET -> INHIBITOR
Related Record Type Details
Structure of 2-AMINO-N-(2,3-DIHYDRO-8-HYDROXY-7-METHOXYIMIDAZO(1,2-C)QUINAZOLIN-5-YL)-5-PYRIMIDINECARBOXAMIDE
METABOLITE -> PARENT
(DEALKYLATION BY CYP3A4), The six healthy male volunteers received a single i.v. infusion of 12 mg copanlisib (2.76 MBq (14C)copanlisib) in a total volume of 40 mL as a 1-h infusion in the morning, 1-h after a light breakfast. 5 Caucasians and 1 Asian with an age 54.8 +/- 5.2 yeas (mean +/- SD, range: 47-61 years) and a BMI of 24.8 kg/m^2. Non-smokers and reported at the most light alcohol use.
AMOUNT EXCRETED
FECAL; URINE
Structure of 2-AMINO-N-(8-(3-(FORMYL(2-HYDROXYETHYL)AMINO)PROPOXY)-2,3-DIHYDRO-7-METHOXYIMIDAZO(1,2-C)QUINAZOLIN-5-YL)-5-PYRIMIDINECARBOXAMIDE
METABOLITE -> PARENT
(DEALKYLATION BY CYP3A4), The six healthy male volunteers received a single i.v. infusion of 12 mg copanlisib (2.76 MBq (14C)copanlisib) in a total volume of 40 mL as a 1-h infusion in the morning, 1-h after a light breakfast. 5 Caucasians and 1 Asian with an age 54.8 +/- 5.2 yeas (mean +/- SD, range: 47-61 years) and a BMI of 24.8 kg/m^2. Non-smokers and reported at the most light alcohol use.
AMOUNT EXCRETED
FECAL; URINE
Structure of 2-AMINO-N-(2,3-DIHYDRO-8-(3-((2-HYDROXYETHYL)AMINO)PROPOXY)-7-METHOXYIMIDAZO(1,2-C)QUINAZOLIN-5-YL)-5-PYRIMIDINECARBOXAMIDE
METABOLITE -> PARENT
(DEALKYLATION BY CYP3A4), The six healthy male volunteers received a single i.v. infusion of 12 mg copanlisib (2.76 MBq (14C)copanlisib) in a total volume of 40 mL as a 1-h infusion in the morning, 1-h after a light breakfast. 5 Caucasians and 1 Asian with an age 54.8 +/- 5.2 yeas (mean +/- SD, range: 47-61 years) and a BMI of 24.8 kg/m^2. Non-smokers and reported at the most light alcohol use.
AMOUNT EXCRETED
FECAL; URINE
Structure of 3-((5-(2-AMINOPYRIMIDINE-5-CARBOXAMIDO)-7-METHOXY-2,3-DIHYDROIMIDAZO(1,2-C)QUINAZOLIN-8-YL)OXY)PROPANOIC ACID
METABOLITE -> PARENT
(DEALKYLATION BY CYP3A4), The six healthy male volunteers received a single i.v. infusion of 12 mg copanlisib (2.76 MBq (14C)copanlisib) in a total volume of 40 mL as a 1-h infusion in the morning, 1-h after a light breakfast. 5 Caucasians and 1 Asian with an age 54.8 +/- 5.2 yeas (mean +/- SD, range: 47-61 years) and a BMI of 24.8 kg/m^2. Non-smokers and reported at the most light alcohol use.
AMOUNT EXCRETED
FECAL; URINE
Structure of 2-AMINO-N-(8-(3-HYDROXYPROPOXY)-7-METHOXY-2,3-DIHYDROIMIDAZO(1,2-C)QUINAZOLIN-5-YL)PYRIMIDINE-5-CARBOXAMIDE
METABOLITE -> PARENT
(DEALKYLATION BY CYP3A4), The six healthy male volunteers received a single i.v. infusion of 12 mg copanlisib (2.76 MBq (14C)copanlisib) in a total volume of 40 mL as a 1-h infusion in the morning, 1-h after a light breakfast. 5 Caucasians and 1 Asian with an age 54.8 +/- 5.2 yeas (mean +/- SD, range: 47-61 years) and a BMI of 24.8 kg/m^2. Non-smokers and reported at the most light alcohol use.
AMOUNT EXCRETED
FECAL; URINE
Structure of BAY-84-5975
METABOLITE ACTIVE -> PARENT
(OXIDATION BY CYP3A4), The six healthy male volunteers received a single i.v. infusion of 12 mg copanlisib (2.76 MBq (14C)copanlisib) in a total volume of 40 mL as a 1-h infusion in the morning, 1-h after a light breakfast. 5 Caucasians and 1 Asian with an age 54.8 +/- 5.2 yeas (mean +/- SD, range: 47-61 years) and a BMI of 24.8 kg/m^2. Non-smokers and reported at the most light alcohol use.
AMOUNT EXCRETED
FECAL; PLASMA; URINE
Related Record Type Details
Structure of COPANLISIB
ACTIVE MOIETY
The six healthy male volunteers received a single i.v. infusion of 12 mg copanlisib (2.76 MBq (14C)copanlisib) in a total volume of 40 mL as a 1-h infusion in the morning, 1-h after a light breakfast. 5 Caucasians and 1 Asian with an age 54.8 +/- 5.2 yeas (mean +/- SD, range: 47-61 years) and a BMI of 24.8 kg/m^2. Non-smokers and reported at the most light alcohol use.
AMOUNT EXCRETED
FECAL; PLASMA; URINE
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966